View Section: Financials
Farmacosmo Statements
CO
Farmacosmo Income Statement
B
M
EUR (except Earnings per share)
Financial
Revenue
Cost of sales
Gross profit
Research and development
Selling, general and administrative
Total operating expenses
Operating income
Interest expense
Other income
Income before tax
Provision for income taxes
Net income
Diluted earnings per share
Shares outstanding after dilution
2023-06-30
%
36.725
100
34.563
94.1
2.162
5.9
—
0
2.266
6.2
3.693
10.1
-1.531
-4.2
-0.419
-1.1
0
0.001
-1.949
-5.3
0.151
0.4
-1.73
-4.7
-0.05
34.677
2022-06-30
%
32.118
100
30.896
96.2
1.222
3.8
—
0
0.946
2.9
1.357
4.2
-0.135
-0.4
-0.235
-0.7
—
0
-0.37
-1.2
-0.084
-0.3
-0.286
-0.9
-0.008
37.642
2021-12-31
%
31.599
100
29.407
93.1
2.192
6.9
—
0
0.931
2.9
1.041
3.3
1.151
3.6
-0.218
-0.7
—
0
0.933
3
0.308
1
0.625
2
0.019
33.46
2021-09-30
%
14.853
100
13.641
91.8
1.213
8.2
—
0
0.399
2.7
0.476
3.2
0.737
5
-0.093
-0.6
—
0
0.644
4.3
0.215
1.4
0.429
2.9
0.013
33.46
View Section: Balance Sheet